{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:20:59Z","timestamp":1772464859414,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Centre Egypt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The role of DNA methylation in the prognosis of breast cancer, particularly concerning small mothers against decapentaplegic 4 (SMAD4) and aldo-keto reductase family 1 member B1 (AKR1B1), remains largely unexplored. This study aimed to investigate the clinical role of SMAD4 and AKR1B1 methylation as noninvasive prognostic biomarkers in breast cancer. The study included 140 individuals. The patients were stratified into two groups based on their diagnostic investigation: women diagnosed with cancer in breast (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200980) and cases with benign lesions in breast (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200930). Additionally, a group of subjects considered as healthy served as the control group (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200930). Methylation levels of SMAD4 and AKR1B1 were quantified using the Methyl II quantitative PCR system. The methylation specificity and sensitivity were examined through performing a receiver operating characteristic (ROC) curve analysis. The association of the methylation of investigated patterns with breast cancer clinical features and response to treatment was also examined. Survival patterns were assesed using Kaplan-Meier analyses. The outcomes revealed that hypermethylation of SMAD4 and AKR1B1 was upregulated in cancerous patients relative to the benign group and healthy subjects. Based on the values of the area under the curve (AUC) (0.945 and 0.935, respectively) for SMAD4 and AKR1B1, both markers demonstrated superior diagnostic accuracy, surpassing conventional biomarkers for instance cancer antigen 15\u2009\u2212\u20093 (CA 15\u2009\u2212\u20093; AUC\u2009=\u20090.698) as well as carcinoembryonic antigen (CEA; AUC\u2009=\u20090.537). Remarkably, SMAD4 and AKR1B1 hypermethylation exhibited a significant association with invasive duct carcinoma (IDC), particularly in early stages, high grades, and cases with lymph node metastasis. A significant difference was observed in methylation status concerning both items and treatment response. Additionally, survival outcomes indicated that hypermethylation of SMAD4 and AKR1B1 was associated with worse DFS and OS. In conclusion, SMAD4 and AKR1B1 methylation may serve as significant epigenetic markers affecting breast cancer prognosis, potentially indicating more aggressive disease and poorer outcomes in these patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-37937-6","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:54:55Z","timestamp":1772218495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of the methylation status of SMAD4 and AKR1B1 genes in a liquid biopsy sample as a prognostic marker for breast cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7104-7194","authenticated-orcid":false,"given":"Menha","family":"Swellam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Emam","family":"Sobeih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-7138","authenticated-orcid":false,"given":"Noha M.","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"12","key":"37937_CR1","doi-asserted-by":"publisher","first-page":"e0278270","DOI":"10.1371\/journal.pone.0278270","volume":"17","author":"J Luo","year":"2022","unstructured":"Luo, J. et al. Identification and validation of DNA methylation markers to predict axillary lymph node metastasis of breast cancer. PLoS One. 17 (12), e0278270 (2022).","journal-title":"PLoS One"},{"key":"37937_CR2","doi-asserted-by":"publisher","first-page":"116559","DOI":"10.1016\/j.biopha.2024.116559","volume":"174","author":"L Trnkova","year":"2024","unstructured":"Trnkova, L. et al. Epigenetic deregulation in breast cancer microenvironment: implications for tumor progression and therapeutic strategies. Biomed. Pharmacother. 174, 116559 (2024).","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"37937_CR3","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.31557\/APJCP.2019.20.8.2523","volume":"20","author":"TF Moghazy","year":"2019","unstructured":"Moghazy, T. F. et al. Methylation of glutathione-S-transferase P1 promotor in Egyptian females with breast cancer. Asian Pac. J. Cancer Prev. 20 (8), 2523\u20132530 (2019).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"37937_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/epigenomes7010006","volume":"7","author":"A Kim","year":"2023","unstructured":"Kim, A. et al. Epigenetic regulation in breast cancer: insights on epidrugs. Epigenomes 7, 6 (2023).","journal-title":"Epigenomes"},{"key":"37937_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bioana.2024.06.004","volume":"1","author":"D Parikha","year":"2024","unstructured":"Parikha, D. & Shah, M. A comprehensive study on epigenetic signatures to monitor disease progression and the response to therapy in breast cancer. Biomedical Anal. 1, 205\u2013217 (2024).","journal-title":"Biomedical Anal."},{"key":"37937_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s43042-021-00185-6","volume":"22","author":"AM Nomair","year":"2021","unstructured":"Nomair, A. M. et al. SCGB3A1 gene DNA methylation status is associated with breast cancer in Egyptian female patients. Egypt. J. Med. Hum. Genet. 22, 66 (2021).","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"8","key":"37937_CR7","doi-asserted-by":"publisher","first-page":"151814","DOI":"10.1016\/j.acthis.2021.151814","volume":"123","author":"H Liu","year":"2021","unstructured":"Liu, H., Xie, H. Q., Zhao, Y., Zhang, W. & Zhang, Y. DNA methylation-mediated down-regulation of TMEM130 promotes cell migration in breast cancer. Acta Histochem. 123 (8), 151814 (2021).","journal-title":"Acta Histochem."},{"key":"37937_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s43042-024-00516-3","volume":"25","author":"MS Mahmoud","year":"2024","unstructured":"Mahmoud, M. S. et al. Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma. Egypt. J. Med. Hum. Genet. 25, 42 (2024).","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"37937_CR9","doi-asserted-by":"publisher","first-page":"394632024125029","DOI":"10.1177\/03946320241250294","volume":"38","author":"M Swellam","year":"2024","unstructured":"Swellam, M. et al. Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma. Int. J. Immunopathol. Pharmacol. 38, 3946320241250294 (2024).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"37937_CR10","first-page":"799","volume":"306","author":"M Miyaki","year":"2003","unstructured":"Miyaki, M. & Kuroki, T. Role of Smad4 (DPC4) inactivation in human cancer. Biochemical and b67uj8iophys. Res. Commun. 306, 799\u2013804 (2003).","journal-title":"Res. Commun."},{"key":"37937_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/978-1-4939-7193-0_17","volume-title":"Pancreatic Cancer","author":"M Korc","year":"2018","unstructured":"Korc, M. Smad4-TGF-\u00df signaling pathways in pancreatic cancer pathogenesis. In Pancreatic Cancer 431\u2013455 (Springer, 2018)."},{"issue":"7","key":"37937_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/1878-0261.12094","volume":"11","author":"A Moustakas","year":"2017","unstructured":"Moustakas, A. & de Herreros, A. G. Epithelial\u2013mesenchymal transition in cancer. Mol. Oncol. 11 (7), 715\u2013717 (2017).","journal-title":"Mol. Oncol."},{"issue":"17","key":"37937_CR13","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.3390\/diagnostics13172769","volume":"13","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. SMAD proteins in TGF-beta signalling pathway in cancer: regulatory mechanisms and clinical applications. Diagnostics (Basel). 13 (17), 2769 (2023).","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"37937_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12967-024-05411-4","volume":"22","author":"AO Giarratana","year":"2024","unstructured":"Giarratana, A. O., Prendergast, C. M., Salvatore, M. M. & Capaccione, K. M. TGF-\u03b2 signaling: critical nexus of fibrogenesis and cancer. J. Transl Med. 22 (1), 594 (2024).","journal-title":"J. Transl Med."},{"issue":"1","key":"37937_CR15","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1038\/s41598-024-57189-6","volume":"14","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. The immune regulation and therapeutic potential of the SMAD gene family in breast cancer. Sci. Rep. 14 (1), 6769 (2024).","journal-title":"Sci. Rep."},{"issue":"6","key":"37937_CR16","doi-asserted-by":"publisher","first-page":"dmm050358","DOI":"10.1242\/dmm.050358","volume":"17","author":"WB Alexander","year":"2024","unstructured":"Alexander, W. B. et al. Smad4 restricts injury-provoked biliary proliferation and carcinogenesis. Dis. Model. Mech. 17 (6), dmm050358 (2024).","journal-title":"Dis. Model. Mech."},{"key":"37937_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0009-2797(02)00193-X","volume":"143\u2013144","author":"D Hyndman","year":"2003","unstructured":"Hyndman, D., Bauman, D. R., Heredia, V. V. & Penning, T. M. The aldo- Keto reductase superfamily homepage. Chem. Biol. Interact. 143\u2013144, 621\u2013631 (2003).","journal-title":"Chem. Biol. Interact."},{"key":"37937_CR18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1158\/0008-5472.CAN-17-2834","volume":"78","author":"A Schwab","year":"2018","unstructured":"Schwab, A. et al. Polyol pathway links glucose metabolism to the aggressiveness of cancer cells. Cancer Res. 78, 1604\u20131618 (2018).","journal-title":"Cancer Res."},{"issue":"4","key":"37937_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1084\/jem.20160903","volume":"214","author":"X Wu","year":"2017","unstructured":"Wu, X. et al. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program. J. Exp. Med. 214 (4), 1065\u20131079 (2017).","journal-title":"J. Exp. Med."},{"key":"37937_CR20","doi-asserted-by":"publisher","first-page":"8890","DOI":"10.1111\/jcmm.15581","volume":"24","author":"R Khayami","year":"2020","unstructured":"Khayami, R., Hashemi, S. R. & Kerachian, M. A. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J. Cell. Mol. Med. 24, 8890\u20138902 (2020).","journal-title":"J. Cell. Mol. Med."},{"issue":"8","key":"37937_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/0046-8177(95)90010-1","volume":"26","author":"P Robbins","year":"1995","unstructured":"Robbins, P. et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum. Pathol. 26 (8), 873\u2013879 (1995).","journal-title":"Hum. Pathol."},{"issue":"3","key":"37937_CR22","first-page":"180","volume":"58","author":"FL Greene","year":"2008","unstructured":"Greene, F. L. & Sobin, L. H. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J. Clin. 58 (3), 180\u2013190 (2008).","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"37937_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/ajcp\/75.5.734","volume":"75","author":"SM Hsu","year":"1981","unstructured":"Hsu, S. M., Raine, L. & Fanger, H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol. 75 (5), 734\u2013738 (1981).","journal-title":"Am. J. Clin. Pathol."},{"key":"37937_CR24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1080\/02841860801971413","volume":"47","author":"SH Kim","year":"2008","unstructured":"Kim, S. H., Seo, B. & Lee, J. Correlation of ultra-sound findings with histology, tumor grade, and biological markers in breast cancer. Acta Oncol. 47, 1531\u20131538 (2008).","journal-title":"Acta Oncol."},{"issue":"4","key":"37937_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","volume":"39","author":"MH Zweig","year":"2013","unstructured":"Zweig, M. H. & Campbell, G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39 (4), 561\u2013577 (2013). PMID: 8472349.","journal-title":"Clin. Chem."},{"key":"37937_CR26","unstructured":"Sathyamoorthi, K., Vp, A., Venkataramana, L. Y. & Prasad, D. V. V. Enhancing breast cancer survival prognosis through omic and non-omic data integration. Clin Breast Cancer. S1526-8209 (24) 00221-0 (2024)."},{"key":"37937_CR27","doi-asserted-by":"publisher","first-page":"e074684","DOI":"10.1136\/bmj-2022-074684","volume":"381","author":"C Taylor","year":"2023","unstructured":"Taylor, C. et al. Breast cancer mortality in 500000 women with early invasive breast cancer diagnosed in England, 1993\u20132015: population based observational cohort study. BMJ 381, e074684 (2023).","journal-title":"BMJ"},{"key":"37937_CR28","doi-asserted-by":"publisher","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman, K. et al. Breast cancer: Biology, biomarkers, and treatments. Int. Immunopharmacol. 84, 106535 (2020).","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"37937_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.21614\/chirurgia.2023.v.118.i.5.p.534","volume":"118","author":"RA Moushaly","year":"2023","unstructured":"Moushaly, R. A. et al. Breast cancer prognosis: A study on mortality indicators. Chirurgia (Bucur). 118 (5), 534\u2013542 (2023).","journal-title":"Chirurgia (Bucur)"},{"issue":"1","key":"37937_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s43141-021-00169-4","volume":"19","author":"A Ramadan","year":"2021","unstructured":"Ramadan, A., Hashim, M., Abouzid, A. & Swellam, M. Clinical impact of PTEN methylation status as a prognostic marker for breast cancer. J. Genet. Eng. Biotechnol. 19 (1), 66 (2021).","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"1","key":"37937_CR31","first-page":"1","volume":"23","author":"E Tarighati","year":"2023","unstructured":"Tarighati, E., Keivan, H. & Mahani, H. A review of prognostic and predictive biomarkers in breast cancer. Clin. Exp. Med. 23 (1), 1\u201316 (2023).","journal-title":"Clin. Exp. Med."},{"key":"37937_CR32","doi-asserted-by":"publisher","first-page":"103551","DOI":"10.1016\/j.jksus.2024.103551","volume":"36","author":"H Alismail","year":"2024","unstructured":"Alismail, H. & Review Merging from traditional to potential novel breast cancer biomarkers. J. King Saud Univ. \u2013 Sci. 36, 103551 (2024).","journal-title":"J. King Saud Univ. \u2013 Sci."},{"key":"37937_CR33","doi-asserted-by":"publisher","first-page":"e0227356","DOI":"10.1371\/journal.pone.0227356","volume":"15","author":"A Perrier","year":"2020","unstructured":"Perrier, A. et al. An updated evaluation of serum sHER2, CA153, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. PLoS One. 15, e0227356 (2020).","journal-title":"PLoS One"},{"key":"37937_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.semcancer.2020.12.011","volume":"83","author":"V Ortiz-Barahona","year":"2022","unstructured":"Ortiz-Barahona, V., Joshi, R. S. & Esteller, M. Use of DNA methylation profiling in translational oncology. Semin Cancer Biol. 83, 523\u2013535 (2022).","journal-title":"Semin Cancer Biol."},{"issue":"24","key":"37937_CR35","doi-asserted-by":"publisher","first-page":"15584","DOI":"10.1080\/07391102.2023.2191122","volume":"41","author":"A Balasundaram","year":"2023","unstructured":"Balasundaram, A. et al. The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from Circulating cell-free DNA of breast cancer and its effect on protein structure - A computational approach. J. Biomol. Struct. Dyn. 41 (24), 15584\u201315597 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"37937_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s43141-021-00154-x","volume":"19","author":"M Swellam","year":"2021","unstructured":"Swellam, M. et al. Alterations of PTEN and SMAD4 Methylation in diagnosis of breast cancer: implications of Methyl II PCR assay. J. Genet. Eng. Biotechnol. 19 (1), 54 (2021).","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"3","key":"37937_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-010-1147-x","volume":"128","author":"E Wiercinska","year":"2011","unstructured":"Wiercinska, E. et al. The tgf-\u03b2\/smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res. Treat. 128 (3), 657\u2013666 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"37937_CR38","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s13277-013-1088-1","volume":"35","author":"NN Liu","year":"2014","unstructured":"Liu, N. N. et al. SMAD4 is a potential prognostic marker in human breast carcinomas. Tumor Biol. 35, 641\u2013650 (2014).","journal-title":"Tumor Biol."},{"key":"37937_CR39","first-page":"73","volume":"2","author":"K Takenaka","year":"2009","unstructured":"Takenaka, K. et al. Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis. Mol. Med. Rep. 2, 73\u201380 (2009).","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"37937_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4274\/jarem.galenos.2021.54264","volume":"11","author":"M Budak","year":"2021","unstructured":"Budak, M. SMAD4 gene methylation May be effective in adenocarcinoma lung cancers. J. Acad. Res. Med. 11 (1), 86\u201389 (2021).","journal-title":"J. Acad. Res. Med."},{"issue":"9","key":"37937_CR41","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1007\/s11033-023-08656-2","volume":"50","author":"Y G\u00fcrsel \u00dcr\u00fcn","year":"2023","unstructured":"G\u00fcrsel \u00dcr\u00fcn, Y., Budak, M. & Ustural\u0131 Keskin, E. Methylation status, mRNA and protein expression of the SMAD4 gene in patients with non-melanocytic skin cancers. Mol. Biol. Rep. 50 (9), 7295\u20137304 (2023).","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"37937_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4103\/1319-3767.82591","volume":"17","author":"AS Sameer","year":"2011","unstructured":"Sameer, A. S. & Siddiqi, M. A. SMAD4 promoter hypermethylation in Kashmiri colorectal cancer cases. Saudi J. Gastroenterol. 17 (4), 297 (2011).","journal-title":"Saudi J. Gastroenterol."},{"issue":"7","key":"37937_CR43","doi-asserted-by":"publisher","first-page":"987","DOI":"10.4161\/epi.28936","volume":"9","author":"O Fotouhi","year":"2014","unstructured":"Fotouhi, O. et al. Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors: an in vivo and in vitro study. Epigenetics 9 (7), 987\u2013997 (2014).","journal-title":"Epigenetics"},{"issue":"2","key":"37937_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2298\/AOO1702017N","volume":"23","author":"A Nikoli\u0107","year":"2017","unstructured":"Nikoli\u0107, A. et al. Analysis of SMAD4 gene promoter methylation in pancreatic and endometrial cancer. Arch. Oncol. 23 (2), 17\u201319 (2017).","journal-title":"Arch. Oncol."},{"key":"37937_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13402-014-0189-1","volume":"37","author":"JS de Groot","year":"2014","unstructured":"de Groot, J. S. et al. Validation of DNA promoter hypermethylation biomarkers in breast cancer\u2014a short report. Cell. Oncol. (Dordr). 37, 297\u2013303 (2014).","journal-title":"Cell. Oncol. (Dordr)"},{"key":"37937_CR46","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.4161\/epi.29632","volume":"9","author":"BM Lindqvist","year":"2014","unstructured":"Lindqvist, B. M., Wingren, S., Motlagh, P. B. & Nilsson, T. K. Whole genome DNA methylation signature of HER2-positive breast cancer. Epigenetics 9, 1149\u20131162 (2014).","journal-title":"Epigenetics"},{"key":"37937_CR47","doi-asserted-by":"publisher","first-page":"117955492412907","DOI":"10.1177\/11795549241290796","volume":"18","author":"M El-Far","year":"2024","unstructured":"El-Far, M., Abdelrazek, M. A., Foda, B. M., Abouzid, A. & Swellam, M. Potential role of AKR1B1 gene methylation in diagnosis of patients with breast cancer. Clin. Med. Insights Oncol. 18, 11795549241290796 (2024).","journal-title":"Clin. Med. Insights Oncol."},{"key":"37937_CR48","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41467-021-22101-7","volume":"12","author":"E Golden","year":"2021","unstructured":"Golden, E. et al. The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in Estrogen receptor-positive breast cancer. Nat. Commun. 12, 1920 (2021).","journal-title":"Nat. Commun."},{"key":"37937_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2017.09.031","volume":"411","author":"K Shukla","year":"2017","unstructured":"Shukla, K., Sonowal, H., Saxena, A., Ramana, K. V. & Srivastava, S. K. Aldose reductase inhibitor, Fidarestat regulates mitochondrial biogenesis via Nrf2\/HO-1\/AMPK pathway in colon cancer cells. Cancer Lett. 411, 57\u201363 (2017).","journal-title":"Cancer Lett."},{"key":"37937_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/654594","volume":"2015","author":"J Krsti\u0107","year":"2015","unstructured":"Krsti\u0107, J., Trivanovi\u0107, D., Mojsilovi\u0107, S. & Santibanez, J. F. Transformin growth factor-beta and oxidative stress interplay: implications in tumorigenesis and cancer progression. Oxid. Med. Cell Longev. 2015, 654594 (2015).","journal-title":"Oxid. Med. Cell Longev."},{"key":"37937_CR51","doi-asserted-by":"publisher","first-page":"18856","DOI":"10.3390\/ijms151018856","volume":"15","author":"T Li","year":"2014","unstructured":"Li, T. & Wang, G. Computer-aided targeting of the PI3K\/AKT\/mTOR pathway: toxicity reduction and therapeutic opportunities. Int. J. Mol. Sci. 15, 18856\u201318891 (2014).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"37937_CR52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/13685538.2019.1597840","volume":"23","author":"N Torrealba","year":"2020","unstructured":"Torrealba, N. et al. TGF-\u03b2\/PI3K\/AKT\/mTOR\/NF-kB pathway. Clinicopathological features in prostate cancer. Aging Male. 23 (5), 801\u2013811 (2020).","journal-title":"Aging Male"},{"issue":"3","key":"37937_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.134","volume":"3","author":"L Hai","year":"2022","unstructured":"Hai, L., Li, L., Liu, Z., Tong, Z. & Sun, Y. Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer. MedComm (2020) 3(3), e134 (2022).","journal-title":"MedComm (2020)"},{"issue":"1","key":"37937_CR54","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12967-025-06495-2","volume":"23","author":"M Hum","year":"2025","unstructured":"Hum, M. & Lee, A. S. G. DNA methylation in breast cancer: early detection and biomarker discovery through current and emerging approaches. J. Transl Med. 23 (1), 465 (2025).","journal-title":"J. Transl Med."},{"issue":"1","key":"37937_CR55","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1007\/s12672-025-02966-6","volume":"16","author":"A Chaudhary","year":"2025","unstructured":"Chaudhary, A. et al. Promoter methylation correlates with reduced SMAD4 expression in patients with breast cancer. Discov Oncol. 16 (1), 1484 (2025).","journal-title":"Discov Oncol."},{"key":"37937_CR56","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1038\/sj.onc.1205923","volume":"21","author":"F Pene","year":"2002","unstructured":"Pene, F. et al. Role of the phosphatidylinositol 3-kinase\/Akt and mTOR\/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21, 6587\u20136597 (2002).","journal-title":"Oncogene"},{"key":"37937_CR57","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MPH.0000000000000329","volume":"37","author":"D King","year":"2015","unstructured":"King, D., Yeomanson, D. & Bryant, H. E. PI3King the lock: targeting the PI3K\/Akt\/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J. Pediatr. Hematol. Oncol. 37, 245\u2013251 (2015).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"37937_CR58","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.drup.2021.100770","volume":"57","author":"L Gao","year":"2021","unstructured":"Gao, L., Wu, Z. X., Assaraf, Y. G., Chen, Z. S. & Wang, L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist. Updat. 57, 100770 (2021).","journal-title":"Drug Resist. Updat"},{"issue":"17","key":"37937_CR59","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1158\/1078-0432.CCR-05-0244","volume":"11","author":"P Alhopuro","year":"2005","unstructured":"Alhopuro, P. et al. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin. Cancer Res. 11 (17), 6311\u20136316 (2005).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"37937_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/0008-5472.CAN-09-3269","volume":"71","author":"P Papageorgis","year":"2011","unstructured":"Papageorgis, P. et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 71 (3), 998\u20131008 (2011).","journal-title":"Cancer Res."},{"issue":"1","key":"37937_CR61","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1078-0432.CCR-06-1467","volume":"13","author":"LH Wang","year":"2007","unstructured":"Wang, L. H. et al. Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin. Cancer Res. 13 (1), 102\u2013110 (2007).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"37937_CR62","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1078-0432.CCR-15-0726","volume":"22","author":"S Inamoto","year":"2016","unstructured":"Inamoto, S. et al. Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through the CCL15-CCR1 chemokine axis. Clin. Cancer Res. 22 (2), 492\u2013501 (2016).","journal-title":"Clin. Cancer Res."},{"key":"37937_CR63","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2017.35.4_suppl.587","volume":"35","author":"I Wasserman","year":"2017","unstructured":"Wasserman, I. et al. SMAD4 loss in colorectal cancer: correlation with recurrence, chemoresistance, and immune infiltrate. J. Clin. Oncol. 35, 587 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"37937_CR64","doi-asserted-by":"publisher","first-page":"e0250634","DOI":"10.1371\/journal.pone.0250634","volume":"16","author":"W Xu","year":"2021","unstructured":"Xu, W. et al. Association of SMAD4 loss with drug resistance in clinical cancer patients: A systematic meta-analysis. PLoS One. 16 (5), e0250634 (2021).","journal-title":"PLoS One"},{"issue":"6","key":"37937_CR65","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41419-024-06838-9","volume":"15","author":"K Li","year":"2024","unstructured":"Li, K. et al. SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR\u2009+\u2009HER2- breast cancer. Cell. Death Dis. 15 (6), 444 (2024).","journal-title":"Cell. Death Dis."},{"issue":"2","key":"37937_CR66","doi-asserted-by":"publisher","first-page":"113714","DOI":"10.1016\/j.celrep.2024.113714","volume":"43","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. EZH2\/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4\/ERK\/c-Myc signaling axis. Cell. Rep. 43 (2), 113714 (2024).","journal-title":"Cell. Rep."},{"issue":"23","key":"37937_CR67","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1158\/1078-0432.CCR-12-0827","volume":"18","author":"Y Cui","year":"2012","unstructured":"Cui, Y. et al. Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin. Cancer Res. 18 (23), 6519\u20136530 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"37937_CR68","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-18-1726","volume":"25","author":"I Wasserman","year":"2019","unstructured":"Wasserman, I. et al. SMAD4 loss in colorectal cancer patients correlates with Recurrence, loss of immune Infiltrate, and chemoresistance. Clin. Cancer Res. 25 (6), 1948\u20131956 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"37937_CR69","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41588-018-0287-5","volume":"51","author":"U Nayar","year":"2019","unstructured":"Nayar, U. et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to Estrogen receptor-directed therapies. Nat. Genet. 51 (2), 207\u2013216 (2019).","journal-title":"Nat. Genet."},{"issue":"Suppl 1","key":"37937_CR70","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.3747\/co.25.3752","volume":"25","author":"A AlFakeeh","year":"2018","unstructured":"AlFakeeh, A. & Brezden-Masley, C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr. Oncol. 25 (Suppl 1), S18\u2013S27 (2018).","journal-title":"Curr. Oncol."},{"issue":"Suppl 6","key":"37937_CR71","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1158\/1538-7445.AM2024-3282","volume":"84","author":"Z Huang","year":"2024","unstructured":"Huang, Z. et al. Endocrine resistance genes driving cross-resistance to current combination therapies in HR-positive breast cancer. Cancer Res. 84 (Suppl 6), 3282 (2024).","journal-title":"Cancer Res."},{"issue":"1","key":"37937_CR72","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-021-01445-0","volume":"21","author":"T Dillinger","year":"2022","unstructured":"Dillinger, T. et al. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Mol. Cancer. 21 (1), 7 (2022).","journal-title":"Mol. Cancer"},{"issue":"3","key":"37937_CR73","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3892\/ol.2015.3442","volume":"10","author":"N Liu","year":"2015","unstructured":"Liu, N., Yu, C., Shi, Y., Jiang, J. & Liu, Y. SMAD4 expression in breast ductal carcinoma correlates with prognosis. Oncol. Lett. 10 (3), 1709\u20131715 (2015).","journal-title":"Oncol. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37937-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37937-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37937-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:01:53Z","timestamp":1772460113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37937-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37937"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37937-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7933"}}